Answers are grounded in this paper and cite their sources.
Introduction Interstitial lung diseases (ILDs) can be caused by mutations in theSFTPA1andSFTPA2genes, which encode the surfactant protein (SP) complex SP-A. Only 11SFTPA1orSFTPA2mutations have so far been reported worldwide, of which five have been functionally assessed. In the framework of ILD molecular diagnosis, we identified 14 independent patients with pathogenicSFTPA1orSFTPA2mutations. The present study aimed to functionally assess the 11 different mutations identified and to accurately describe the disease phenotype of the patients and their affected relatives. Methods The consequences of the 11SFTPA1orSFTPA2mutations were analysed bothin vitro, by studying the production and secretion of the corresponding mutated proteins andex vivo, by analysing SP-A expression in lung tissue samples. The associated disease phenotypes were documented. Results For the 11 identified mutations, protein production was preserved but secretion was abolished. The expression pattern of lung SP-A available in six patients was altered and the family history reported ILD and/or lung adenocarcinoma in 13 out of 14 families (93%). Among the 28SFTPA1 or SFTPA2mutation carriers, the mean age at ILD onset was 45 years (range 0.6–65 years) and 48% underwent lung transplantation (mean age 51 years). Seven carriers were asymptomatic. Discussion This study, which expands the molecular and clinical spectrum of SP-A disorders, shows that pathogenicSFTPA1orSFTPA2mutations share similar consequences for SP-A secretion in cell models and in lung tissue immunostaining, whereas they are associated with a highly variable phenotypic expression of disease, ranging from severe forms requiring lung transplantation to incomplete penetrance.
No takes yet. Share an insight, caveat, or question.
Legendre et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: